A N Orekhov Selected Research

Tablets

1/2002	[Hypotensive effect of long-acting garlic tablets allicor (a double-blind placebo-controlled trial)].
1/2001	[Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A N Orekhov Research Topics

Disease

28	Atherosclerosis 01/2018 - 09/2001
7	Cardiovascular Diseases (Cardiovascular Disease) 08/2017 - 01/2005
5	Inflammation (Inflammations) 01/2017 - 01/2013
3	Atherosclerotic Plaque (Atheroma) 08/2013 - 09/2001
2	Infections 01/2018 - 01/2004
2	Pathologic Processes 04/2017 - 01/2013
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017 - 08/2016
2	Fibrosis (Cirrhosis) 01/2017 - 05/2016
2	Carotid Artery Diseases 12/2015 - 07/2012
2	Disease Progression 08/2013 - 05/2013
1	Mucolipidoses (Sialidosis) 01/2018
1	Neoplasms (Cancer) 01/2018
1	Immune System Diseases (Immune Disorders) 01/2018
1	Paresthesia (Dysesthesia) 08/2017
1	Starvation 01/2017
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2016
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 10/2016
1	Myoglobinuria 08/2016
1	Mitochondrial Myopathies (Mitochondrial Myopathy) 08/2016
1	Hyperlipidemias (Hyperlipidemia) 01/2016
1	Dyslipidemias (Dyslipidemia) 01/2016
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2005
1	Atrophic Gastritis 01/2004
1	Metaplasia 01/2004
1	Breast Diseases (Breast Disease) 01/2004
1	Premenstrual Syndrome (Premenstrual Tension) 01/2004
1	Fibroma (Fibromatosis) 01/2004
1	Mastodynia 01/2004
1	Dysmenorrhea (Menstrual Pain) 01/2004
1	Stomach Neoplasms (Stomach Cancer) 01/2004
1	Hypertension (High Blood Pressure) 01/2002
1	Intracranial Arteriosclerosis (Cerebral Atherosclerosis) 01/2001

Drug/Important Bio-Agent (IBA)

11	LipidsIBA 01/2017 - 09/2001
10	CholesterolIBA 01/2017 - 09/2001
7	oxidized low density lipoproteinIBA 01/2017 - 10/2005
4	Lipoproteins (Lipoprotein)IBA 05/2016 - 01/2013
3	karinatIBA 08/2017 - 01/2004
3	Mitochondrial DNA (mtDNA)IBA 04/2017 - 01/2015
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 09/2001
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 08/2002
3	Messenger RNA (mRNA)IBA 08/2013 - 10/2011
2	Phytoestrogens (Phytoestrogen)IBA 08/2017 - 06/2006
2	HDL LipoproteinsIBA 01/2017 - 01/2016
2	Cholesterol Esters (Cholesteryl Esters)IBA 05/2016 - 08/2002
2	Biomarkers (Surrogate Marker)IBA 03/2016 - 07/2012
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2016 - 07/2012
2	Pharmaceutical PreparationsIBA 01/2005 - 01/2004
2	AntioxidantsIBA 01/2004 - 01/2004
2	PowdersIBA 01/2002 - 01/2001
2	TabletsIBA 01/2002 - 01/2001
1	Neuraminidase (Sialidase)IBA 01/2018
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2017
1	SphingomyelinsIBA 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017
1	trimethyloxamine (trimethylamine N-oxide)IBA 01/2017
1	CytokinesIBA 01/2017
1	ChemokinesIBA 01/2017
1	Pattern Recognition ReceptorsIBA 10/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2016
1	NLR ProteinsIBA 10/2016
1	LectinsIBA 08/2016
1	Cytochromes b (Cytochrome b)IBA 08/2016
1	Antisense OligonucleotidesIBA 03/2016
1	MicroRNAs (MicroRNA)IBA 03/2016
1	Biological ProductsIBA 01/2016
1	SugarsIBA 01/2016
1	AcetylglucosamineIBA 01/2016
1	ApolipoproteinsIBA 01/2016
1	Nonesterified Fatty Acids (NEFA)IBA 01/2016
1	GalactosamineIBA 01/2016
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 01/2016
1	Triglycerides (Triacylglycerol)IBA 01/2016
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016
1	MonoglyceridesIBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 03/2015
1	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2013
1	Indicators and Reagents (Reagents)IBA 07/2012
1	LDL CholesterolIBA 07/2012
1	trans-sialidaseIBA 11/2001
1	LipofuscinIBA 09/2001

Therapy/Procedure

4	Therapeutics 01/2018 - 01/2004